Floatz logo

64Cu-Tz-SarAr

Metastatic Pancreatic Ductal Adenocarcinoma

Memorial Sloan Kettering Cancer CenterPhase 1Active
CC
41/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
81/ 100

Competitive context

25 Active assets in the Metastatic Pancreatic Ductal Adenocarcinoma cohort.

Asset / SponsorPhaseRating
Fludarabine
Beijing Biotech
Phase 2B
Cyclophosphamide
City of Hope Medical Center
Phase 2B
Mitazalimab
University of Pennsylvania
Phase 2B
Botensilimab
Benjamin Spieler
Phase 2B
IMMUNOGLOBULIN G1, ANTI-(HUMAN INTERLEUKIN-1 RECEPTOR ACCESSORY PROTEIN) (HUMAN-MUS MUSCULUS MONOCLONAL CAN04 .GAMMA.1-CHAIN), DISULFIDE WITH HUMAN-MUS MUSCULUS MONOCLONAL CAN04 .KAPPA.-CHAIN, DIMER
Cantargia AB
Phase 1/2B

View all 31 →

Same molecule, other indications

64Cu-Tz-SarAr is also rated in:

malignant pancreatic neoplasmDormant
C
Indicative ·
39 / 100
View asset →
pancreatic ductal adenocarcinomaDormant
C
Indicative ·
37 / 100
View asset →
pancreatic neoplasmDormant
C
Indicative ·
36 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →